Xiaoyao Pill Regulates Gut Microbiota and Tryptophan Metabolism to Alleviate Depression Induced by Chronic Stress in Rats.
10.1007/s11655-025-4211-4
- Author:
Ying LIU
1
;
Jie SHEN
1
;
Xing ZHANG
1
;
Fan PING
2
;
Kai QYU
3
;
Xia SHEN
4
Author Information
1. College of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, 712046, China.
2. Department of Pharmacy, The First Affiliated Hospital of Jiao Tong University, Xi'an, 710061, China.
3. Shaanxi Provincial Hospital of Chinese Medicine, Xi'an, 710003, China.
4. College of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, 712046, China. shenx0@sntcm.edu.cn.
- Publication Type:Journal Article
- Keywords:
Xiaoyao Pill;
chronic stress;
depression;
intestinal microbiota;
tryptophan metabolism
- MeSH:
Animals;
Tryptophan/metabolism*;
Drugs, Chinese Herbal/therapeutic use*;
Gastrointestinal Microbiome/drug effects*;
Rats, Sprague-Dawley;
Depression/blood*;
Male;
Stress, Psychological/drug therapy*;
Behavior, Animal/drug effects*;
Rats;
Chronic Disease;
Hippocampus/drug effects*
- From:
Chinese journal of integrative medicine
2025;31(12):1087-1096
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the antidepressant effects of Xiaoyao Pill (XYP) by exploring its interactions with gut microbiota and tryptophan metabolism.
METHODS:Utilizing network pharmacology, the functional substance groups, key targets, and pathways of XYP in the treatment of depression were identified. The chronic unpredictable mild stress (CUMS) protocol was implemented in male Sprague-Dawley rats to establish depression model. Thirty rats were randomly divided into 3 groups according to their body weight (10 for each): control, CUMS and XYP groups (1.8 g/kg). After 28-day interventions, behavioral phenotyping including sucrose preference test (SPT) and open field test (OFT) were performed. Biochemical validation encompassed enzyme-linked immunosorbent assay for serum cortisol, hematoxylin-eosin histopathology, and immunohistochemistry. Liquid chromatography-mass spectrometry was utilized to profile serum metabolites, while fecal samples underwent metagenomic sequencing for gut microbiota characterization.
RESULTS:Network pharmacology studies predicted that key components can protect the nervous system by regulating inflammatory pathways through the blood-brain barrier. SPT and OFT showed that XYP treatment significantly ameliorated depressive-like behaviors (all P<0.05). XYP treatment also restored hippocampal neuronal density, increased serum neurotransmitter levels of neurotransmitters such as 5-hydroxytryptamine and vasoactive intestinal peptide, and while suppressing inflammatory markers such as tumor necrosis factor-alpha, interleukin-1 beta (IL-1 β), and IL-6 (all P<0.05). Metagenomics revealed significant restructuring of gut microbiota, notably the regulation of Parabacteroides distasonis (P<0.05). Non-targeted metabolomics analysis showed that the level of metabolites in the tryptophan and kynurenine pathway significantly changed (variable importance in the projection >1, P<0.05), and the change of metabolic flux was significantly correlated with behavioral improvement (P<0.05).
CONCLUSIONS:XYP exerts antidepressant effects by increasing neurotransmitter levels, reducing inflammatory makers and modulating Parabacteroides distasonis. Through further exploration of metabolomics, we found that XYP may play a protective role in depression by regulating tryptophan metabolism.
